. . . . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en payares de 2014"@ast . . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@nl . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@en . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@en . . . . "scientific article published on 28 November 2014"@en . . "388" . . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@en . . . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@nl . . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u043B\u0438\u0441\u0442\u043E\u043F\u0430\u0434\u0456 2014"@uk . . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@nl . . . "Irfan Maghfoor" . . . . . . . . . "1" . "25429839" . . . . "2014-11-28T00:00:00Z"^^ . "32" . . . "Tusneem Ahmed M Elhassan" . . "1013516423" . . "Saad Akhtar" . . . . . . . . . . "im November 2014 ver\u00F6ffentlichter wissenschaftlicher Artikel"@de . . . "wetenschappelijk artikel"@nl . . . . "10.1007/S12032-014-0388-7" . . "Muhammad Shahzad Rauf" . . . . . "High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy"@en .